IFNA2, interferon alpha 2, 3440

N. diseases: 355; N. variants: 1
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.080 GeneticVariation disease BEFREE IFNA1- rs1831583 and IFNA2- rs649053 are associated with the development of HCC. 29080269 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.080 GeneticVariation disease BEFREE Human hepatoma (Huh-7 and Huh-7.5) and primary HFLCs were incubated with TNF and/or recombinant IFNA2A, IFNB, IFNL1, and IFNL2 before or during HCV infection. 28456632 2017
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.080 Biomarker disease BEFREE Here, we investigated the effects of telbivudine (LdT), entecavir (ETV) and interferon-α2b (IFN-α2b) on HBV-related HCC. 28192212 2017
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.080 Biomarker disease BEFREE Interferon-α2b gene-modified human bone marrow mesenchymal stem cells inhibit hepatocellular carcinoma by reducing the Notch1 levels. 26518164 2015
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.080 Biomarker disease BEFREE Interferon-α2b (IFN-α2b) reduces proliferation and increases apoptosis in hepatocellular carcinoma cells by decreasing β-catenin/TCF4/Smads interaction. 24950290 2014
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.080 Biomarker disease BEFREE He had initially received interferon α-2b and RBV for 2 years, and later developed hepatocellular carcinoma (HCC). 21865660 2012
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.080 AlteredExpression disease BEFREE Inhibitory effect of interferon-alpha-2b on expression of cyclooxygenase-2 and vascular endothelial growth factor in human hepatocellular carcinoma inoculated in nude mice. 19058305 2008
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.080 Biomarker disease BEFREE Recombinant human interferon alpha 2a as well as natural human interferons alpha and beta significantly suppressed the production of hepatitis B surface antigen by PLC/PRF/5 cells (which have been established from a human primary hepatocellular carcinoma and proven to carry the hepatitis B virus DNA) and inhibited proliferation of these cells in vitro. 2464737 1988